ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OXB Oxford Biomedica Plc

201.00
3.80 (1.93%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica Plc LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.80 1.93% 201.00 199.20 203.50 202.50 194.20 199.00 240,015 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medicinal Chems,botanicl Pds 139.99M -45.16M -0.4676 -4.31 194.61M

Oxford Biomedica PLC Director/PDMR Shareholding (1337G)

24/05/2017 1:55pm

UK Regulatory


Oxford Biomedica (LSE:OXB)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Oxford Biomedica Charts.

TIDMOXB

RNS Number : 1337G

Oxford Biomedica PLC

24 May 2017

Director Dealings / Market Share Purchase

Oxford, UK - 24 May 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, discloses that Dr Lorenzo Tallarigo, Chairman of the Group, on Wednesday 24 May 2017 acquired ordinary shares in the Group as set out below under the market share purchase agreement outlined in the Group's announcement on 15 December 2015.

Under the market share purchase agreement, one-third of Dr Tallarigo's fees as Chairman, after tax, are to be used to purchase shares in Oxford BioMedica PLC on a monthly basis at the prevailing market price.

 
                                                             Interest after 
                                                                purchase 
-----------  ---------  ----------  ----------------  ---------------------------- 
 Director      Title      Price        Number of         Number       % of total 
   / PDMR                per share   Ordinary Shares   of Ordinary      issued 
                            (p)         acquired         Shares      share capital 
-----------  ---------  ----------  ----------------  ------------  -------------- 
Dr Lorenzo 
 Tallarigo   Chairman      5.1p          53,260        1,940,940        0.06% 
-----------  ---------  ----------  ----------------  ------------  -------------- 
 

The issued share capital of the Group is 3,088,326,065 ordinary 1p shares.

-Ends-

 
 For further information, 
  please contact: 
  Oxford BioMedica plc:                     Tel: +44 (0)1865 
   John Dawson, Chief Executive              783 000 
   Officer 
   Tim Watts, Chief Financial 
   Officer 
  Financial and corporate communications    Tel: +44 (0)20 3709 
   enquiries:                                5700 
   Consilium Strategic Communications 
   Mary-Jane Elliott/Matthew 
   Neal/Chris Welsh/Laura Thornton 
 

Notes for editors

About Oxford BioMedica(R)

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy company focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R) ) through which the Group develops in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 250 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBDGDUSUDBGRS

(END) Dow Jones Newswires

May 24, 2017 08:55 ET (12:55 GMT)

1 Year Oxford Biomedica Chart

1 Year Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

1 Month Oxford Biomedica Chart

Your Recent History

Delayed Upgrade Clock